The proceeds will support the company’s activities with its ongoing clinical trial of i-FACTOR peptide enhanced bone graft for cervical spine applications. The financing will also help accelerate development of new products.
More Articles on Devices:
Orthopedic, Spine Device Companies Brace for 2.3% Tax Impact
Biovenus Opens Dutch Headquarters
Sens. Amy Klobuchar, Al Franken Seek to Delay Medical Device Tax
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
